Roche Q1 sales up 10%, confirms 2022 outlook

  div classBodysc17zpet90 cdBBJodivpReuters – Swiss drugmaker Roches first quarter sales rose 10, driven by drugs including Ocrevus against multiple sclerosis as well as Hemlibra against haemophilia, and on strong U.S. demand for rapid COVID19 antigen tests.

  Quarterly sales rose to 16.44 billion Swiss francs 17.17 billion, up from 14.93 billion Swiss francs in the yearearlier period, the company said on Monday. That was slightly above a market consensus of about 16 billion francs.pdivdivdiv classBodysc17zpet90 cdBBJodiv

  Roche also confirmed its guidance for 2022.

  1 0.9577 Swiss francs

  Reporting by Ludwig Burger Editing by Miranda Murray

  divdivdiv classBodysc17zpet90 cdBBJodivdivdiv

Be the first to comment

Leave a Reply

Your email address will not be published.